BMJ11d
Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness
Objective Considering the diverse aetiologies and immunodysregulatory statuses observed in each patient with rheumatoid arthritis (RA), stratification based on peripheral blood immunophenotyping holds ...
BMJ1d
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis
4 Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte, Universidade de Lisboa, and Centro Académico deMedicina de Lisboa, Lisbon, Portugal 5 Oxford NIHR Biomedical Research Centre ...
BMJ1d
Interleukin 27 attenuates collagen-induced arthritis
Department of Physiology, Yong Loo Lin School of Medicine, University of Singapore, Singapore Professor F Y Liew, Division of Immunology, Infection and Inflammation, Glasgow Biomedical Research Centre ...
BMJ1d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ1d
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...
BMJ4d
Update of EULAR recommendations for the treatment of systemic sclerosis
The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the ...
BMJ1d
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
BMJ1d
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ7d
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...
BMJ13d
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Objectives Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA. Methods FOREMOST (NCT03747939) ...
BMJ12d
Studies with pain rating scales.
Good correlation has been shown between pain scores derived from 4 different rating scales. The correlation was maintained when presentation of the scales was separated by a series of questions and by ...
BMJ11d
AB0341 EFFICACY AND DRUG SURVIVAL AFTER MULTIPLE-SWITCHING FROM ADALIMUMAB ORIGINATOR TO THE BIOSIMILARS ABP501 AND SB5: A REAL-LIFE STUDY
1 Azienda Ospedaliero Universitaria Città Della Salute e della Scienza di Torino, Rheumatology Unit, Turin, Italy 2 Azienda Ospedaliero Universitaria di Parma, Department of Medicine, Internal ...